Retatrutide, a new weight loss from Eli Lilly, isn’t even out yet. Lilly’s drug works similarly to semaglutide, which is sold by Novo Nordisk under the brand names Ozempic and Wegovy. It mimics a gut hormone responsible which binds to the GLP-1 receptor for regulating blood sugar levels and your perception of hunger, in effect suppressing your appetite. It’s being hailed as a first-of-its-kind “Triple G” drug because it targets the GLP-1 receptor, the GIP receptor, and the GCG receptor. “I was 53 with the dad-bod gut,” Terry’s business partner who chose to remain anonymous told Wired.